Oncology

The American Cancer Society forecasts that 1,638,910 new cancer cases will occur in the United States in 2012. As cancer rates worldwide are increasing, the oncological sector of the pharmaceutical industry is growing fast and it will continue to provide business opportunities in the next years. However, cancer trials are some of the most complex, time consuming and expensive across all therapeutic areas. What are the new paths to success in this lucrative but challenging market?

Find out the answer in the reports, books, and subscriptions listed under Research and Markets’ Oncology category. Our top-quality publications from industry experts cover every aspect of cancer drug therapy, with a focus on: Lung Cancer, Breast Cancer, Prostate Cancer, Leukaemia, Lymphoma, Ovarian Cancer, Colon Cancer, Cervical Cancer, Brain Cancer and Bladder Cancer. So read on for the latest clinical trials, pipeline reviews, industry news, and commercial opportunities.

Key players featured in our publications include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Wyeth, and many more. Show Less ... more

• EpiCast Report: Non-Small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2022

  EURO€ 3,071.00USD$ 3,995.00GBP£ 2,584.00AUD$ 3,907.00JPY¥ 394,438.00SEK 26 231,00CHF 3'765.00CAD$ 4,071.00 GlobalData, Mar 2013 , Pages: 73
  EpiCast Report: Non-Small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2022 Lung cancer is a disease of uncontrolled cell growth in the lung tissues It is one of the most commonly occurring cancers...

• Bone Cancer - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 162
  Bone Cancer – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Bone Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Non-Hodgkin Lymphoma - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 493
  Non-Hodgkin Lymphoma – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Non-Hodgkin Lymphoma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This...

• Colon Carcinoma - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 43
  Colon Carcinoma – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Colon Carcinoma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...

• Chronic Back Pain - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 55
  Chronic Back Pain – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Chronic Back Pain - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...

• Nonhematologic Malignancy - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 35
  Nonhematologic Malignancy – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Nonhematologic Malignancy - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....

• Chemotherapy Induced Anemia - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 53
  Chemotherapy Induced Anemia – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Chemotherapy Induced Anemia - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic...

• Overactive Bladder - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 132
  Overactive Bladder – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Overactive Bladder - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This...

• Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 157
  Graft Versus Host Disease (GVHD) – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2013', provides an overview of the indication’s...

• Diabetes - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 359
  Diabetes – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Diabetes - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

• Malaria - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 269
  Malaria – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Malaria - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

• Neurodegenerative Diseases - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 228
  Neurodegenerative Diseases – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Neurodegenerative Diseases - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic...

• Renal Cell Carcinoma - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 334
  Renal Cell Carcinoma – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Renal Cell Carcinoma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This...

• Metastatic Cancer - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 475
  Metastatic Cancer – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Metastatic Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...

• Metastatic Melanoma - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 375
  Metastatic Melanoma – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Metastatic Melanoma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This...

• Kidney Transplantation - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 127
  Kidney Transplantation – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Kidney Transplantation - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....

• Type 2 Diabetes - Pipeline Review, H1 2013

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 Global Markets Direct, Mar 2013 , Pages: 432
  Type 2 Diabetes – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Type 2 Diabetes - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...

• Multiple Sclerosis - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 605
  Multiple Sclerosis – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Multiple Sclerosis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This...

• Kidney Disease - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 324
  Kidney Disease – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Kidney Disease - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Neutropenia - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 104
  Neutropenia – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Neutropenia - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Hypertension - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 289
  Hypertension – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Hypertension - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Atlas of Hematopathology

  EURO€ 136.00USD$ 177.00GBP£ 114.00AUD$ 173.00JPY¥ 17,469.00SEK 1 162,00CHF 167.00CAD$ 180.00 Elsevier Science and Technology, Mar 2013 , Pages: 756
  As the definitive diagnostic atlas of the diseases of the hematopoietic system, the Atlas of Hematopathology appeals to a wide range of people who are being trained in a variety of medical fields or...

• Metastatic Brain Tumor Global Clinical Trials Review, H1, 2013

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 GlobalData, Feb 2013 , Pages: 79
  Metastatic Brain Tumor Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Metastatic Brain Tumor Global Clinical Trials Review, H1, 2013" provides data on the Metastatic Brain...

• Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 100
  Peripheral T-Cell Lymphomas (PTCL) – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2013', provides an overview of the indication’s...

• Medullary Thyroid Cancer - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 58
  Global Markets Direct's, 'Medullary Thyroid Cancer - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline This report provides information on the therapeutic development...

• Anaplastic Thyroid Cancer - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 51
  Anaplastic Thyroid Cancer – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Anaplastic Thyroid Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....

• Bone Metastasis - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 137
  Bone Metastasis – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Bone Metastasis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...

• Malignant Pleural Mesothelioma - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 100
  Global Markets Direct's, 'Malignant Pleural Mesothelioma - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline This report provides information on the therapeutic...

• Neuroendocrine Carcinoma - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 25
  Neuroendocrine Carcinoma – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Neuroendocrine Carcinoma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....

• T-Cell Leukemia - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 74
  T-Cell Leukemia – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'T-Cell Leukemia - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...

• Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 168
  Global Markets Direct's, 'Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic...

• Mantle Cell Lymphoma - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 177
  Mantle Cell Lymphoma – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Mantle Cell Lymphoma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This...

• Neuroblastoma - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 139
  Neuroblastoma – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Neuroblastoma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Oral Cancer - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 40
  Oral Cancer – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Oral Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Fallopian Tube Cancer - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 158
  Fallopian Tube Cancer – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Fallopian Tube Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....

• Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 203
  Diffuse Large B-Cell Lymphoma – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic...

• Small-Cell Lung Cancer - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 223
  Small-Cell Lung Cancer – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Small-Cell Lung Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....

• Brain Cancer - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 129
  Brain Cancer – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Brain Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Follicular Lymphoma - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 154
  Follicular Lymphoma – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Follicular Lymphoma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This...

• Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 114
  Gastrointestinal Stromal Tumor (GIST) – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2013', provides an overview of the indication’s...

• Medulloblastoma - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 49
  Medulloblastoma – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Medulloblastoma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...

• Hodgkin Lymphoma - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 214
  Hodgkin Lymphoma – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Hodgkin Lymphoma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...

• Melanoma - Pipeline Review, H1 2013

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 Global Markets Direct, Feb 2013 , Pages: 195
  Melanoma – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Melanoma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

• Brain Metastasis - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 65
  Brain Metastasis – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Brain Metastasis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...

• Nasopharyngeal Cancer - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 84
  Global Markets Direct's, 'Nasopharyngeal Cancer - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline This report provides information on the therapeutic development...

• Rectal Cancer - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 88
  Rectal Cancer – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Rectal Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

• B-Cell Leukemia - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 92
  B-Cell Leukemia – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'B-Cell Leukemia - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...

• Hepatic (Liver) Tumor - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 38
  Hepatic (Liver) Tumor – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Hepatic (Liver) Tumor - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....

• Endometrial Cancer - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 133
  Endometrial Cancer – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Endometrial Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This...

• Metastatic Liver Cancer - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 60
  Metastatic Liver Cancer – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Metastatic Liver Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....